Drugs in the Workplace
- Intro to Workplace Drug Abuse
- A Drug-Free Workplace
- Symptoms and Intervention
- Signs of Drug Abuse
- Helplines for Employees
- Drug-Free Workplaces
- Facts and Figures
- Frequently Asked Questions
- Industries & Economic Sectors
- Substance Abuse Awareness
- Uncovering the Hidden Signs
- Written Policy Statement
- Saving Lives and Money
- Training Supervisors

 




 





Skip Navigation

Glutethimide & Methaqualone

Glutethimide (Doriden®) was introduced in 1954 and methaqualone ("Quaalude" Sopor®) in 1965 as safe barbiturate substitutes. Experience demonstrated, however; that their addiction liability and the severity of withdrawal symptoms were similar to those of barbiturates. By 1972, "luding out," taking methaqualone with wine, was a popular college pastime. Excessive use leads to tolerance, dependence, and withdrawal symptoms similar to those of barbiturates. In the United States, the marketing of methaqualone pharmaceutical products stopped in 1984, and methaqualone was transferred to Schedule I of the CSA. In 1991, glutethimide was transferred into Schedule II in response to an upsurge in the prevalence of diversion, abuse, and overdose deaths. Today, there is little medical use of glutethimide in the United States.